IL2 and neoplasm: Mice of the combination therapy (F16–IL2+temozolomide) exhibited the strongest therapeutic benefit, with an average tumour volume of 14 mm3, compared with those of temozolomide alone (33.5 mm3), F16–IL2 alone (36.8 mm3), and the control group (52 mm3).